Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivanisiran for Dry Eye in Subjects with Sjögren’s Syndrome
2022-002158-15Phase 3Active
- Sponsor
- Sylentis
- Start
- Jul 2022
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of tivanisiran in dry eye syndrome (DED) and Sjögren's syndrome, sponsored by Sylentis. Primary endpoint: Mean change in total corneal fluorescein staining score from baseline to Day 85. Started Jul 2022; status: active.
02
Drugs
tivanisiran
03
Conditions
dry eye syndrome (DED)Sjögren's syndrome
Beyond the preview
Go deeper on 2022-002158-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002158-15.